Who is Jack Teixeira, the Pentagon Documents Leaker?

The Food and Drug Administration (FDA) has approved NovoTTF-100L System from Novocure in conjunction with pemetrexed plus platinum-based chemotherapy to treat unresectable malignant pleural mesothelioma (MPM).

the first MPM treatment in 15 years to receive the FDA’s approval—the last approved treatment was pemetrexed.

NovoTTF-100L System is a tumor treating fields (TTF) device indicated for treating tumors that cannot be removed by surgery. According to Novocure, in TTF therapy, low intensity electric fields are used to disrupt cell division in cancerous tumors. It is a non-invasive treatment. The portable NovoTTF-100L System is used in the patient’s home by a licensed physician who may train the patient’s caregivers. Patients receive the electric fields through transducer arrays connected to the device and the patient’s chest. It is indicated for use at least 18 hours a day with small breaks and can be plugged into a power supply or operate with a rechargeable battery.

Shares of NovoCure are up more than 6% in premarket trading after the company announced it won regulatory approval for its #mesothelioma #treatment, NovoTTF-100L #System. #BiotechnologyReport #News https://t.co/f6Xf6i3Jb6

— Biotechnology Report (@BiotechRpt) ٢٧ مايو ٢٠١٩

“we have been developing and commercializing Tumor treatment Fields to extend survivals in some of the most aggressive forms of cancer, Since 2000 ,” said Bill Doyle, executive chairman of Novocure, in a press release. 

He added, "that the approval of the FDA, On Mesothelioma treatment NovoTTF-100L for Patients as the First FDA Approved Treatment for MPM As the first FDA-approved stem cell indicator, this is a major event for Novocure. Patients, caregivers and healthcare providers who have partnered with us to make this possible.

“MPM is a devastating disease, with only 10 to 20 percent of patients being candidates for surgery to remove the tumor,” said Mary Hesdorffer, NP, executive director of the Mesothelioma Applied Research Foundation. “Typically, mesothelioma patients who cannot have surgery receive palliative care to mitigate their symptoms. NovoTTF-100L provides unresectable MPM patients with a treatment option that may improve survival. We are encouraged by the FDA approval and hope it is just the beginning of innovation in the treatment of this aggressive disease.”

How NovoTTF™-100L System Works ?

Tumor Treating Fields is a relatively new technology that has gained traction as a treatment for some of the most aggressive cancers.

NovoTTF-100L uses low-intensity alternating electric fields, which are tuned to interfere with the division of cancer cells. For mesothelioma, the currents are delivered noninvasively to the upper torso.

The system is intended for continuous home use by mesothelioma patients.

TTF therapy was tested in the phase 2 STELLAR trial, which included 80 patients with unresectable, untreated mesothelioma who received continuous 150 kHz TTF in combination with pemetrexed and platinum. Patients were followed for at least one year. The study’s primary endpoint was overall survival. Outcomes were compared to those of historical controls.

Median age among the total cohort was 67 years (range 27-78 years). Most patients (84%) were male, 66% had epithelioid histology, more than half (56%) were smokers, 44% had an ECOG Performance Status of 1, and 16% had metastatic disease.

68% of patients complied with treatment For the first three months, (16.3 hours/day). Median overall survival was 18.2 months, about six months more than that of historical controls, and median progression-free survival was 7.6 months in the TTF group versus 5.7 months in the historical control group. No serious adverse events were observed, and the most common side effect was skin rash or irritation, which went away after stopping treatment.